| The Wall Street Journal Western Edition 1999 Thomas M. Burton |
| Title | Subject | Authors |
|---|
| Abbott acquires co-marketing rights to arthritis drug.(arthritis pain relief drug, Mobic, is made by Germany's Boehringer Ingelheim GmbH)(Abstract) | Business, general | Thomas M. Burton |
| Arthritis-drug ads won't name product.(Monsanto's G.D. Searle pharmaceuticals unit will not mention Celebrex in its new television ads for the drug)(Advertising) | Business, general | Scott Kilman, Thomas M. Burton |
| Lilly, in coup, settles for only $4 million portion of patent challenge to Prozac.(Eli Lilly & Co.)(Abstract) | Business, general | Thomas M. Burton |
| Monsanto arthritis-pain drug, Celebrex, surpasses Viagra's early sales success.(Abstract) | Business, general | Thomas M. Burton |
| Monsanto drug could ignite marketing war; drug approved by FDA to treat arthritis pain may not cause ulcers.(Abstract) | Business, general | Thomas M. Burton, Rochelle Sharpe |
| Monsanto's arthritis drug, Celebrex, shows strong sales in its first week.(Abstract) | Business, general | Robert Langreth, Thomas M. Burton |
| Monsanto's arthritis drug sells briskly.(Abstract) | Business, general | Thomas M. Burton |
| SmithKline is expected to sell two units; sale of pharmacy-benefits, clinical-lab businesses increases focus on drugs.(SmithKline Beecham PLC)(Abstract) | Business, general | Steven Lipin, Robert Langreth, Thomas M. Burton |
| Zeneca sues Eli Lilly over Evista promotion.(Abstract) | Business, general | Robert Langreth, Thomas M. Burton, Frances A. McMorris |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
